Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysis.

In the low PD-L1 expression group, the PFS benefit was significantly greater for patients treated with TP chemotherapy than for those treated with PF chemotherapy ( P = 0.01) and the OS benefit was numerically in favor of TP chemotherapy, although this association did not reach statistical significance ( P = 0.32; Fig. 4 c and d) ( Table S3 ) .

also in 111,027 other papers